中国生物科技服务(08037)_个股概要_股票价格_最新资讯_行情走势_历史数据 - 老虎社区

应交易所要求，美/港股行情延时15分钟展示，下载APP即可免费查看实时行情。

关闭

08037 中国生物科技服务

休市中 07-25 16:08:05

0.680

-0.070

-9.33%

最高0.750	最低0.680	成交量44.40万
今开0.750	昨收0.750	日振幅9.33%
总市值6.63亿	流通市值6.63亿	总股本9.76亿
成交额31.09万	换手率0.05%	流通股本9.76亿
市净率2.50	ROE-68.71%	每股收益-0.20
52周最高0.920	52周最低0.250	市盈率-3.32
股息0.00	股息收益率0.00	ROA-15.34%

北京优虎网络科技有限公司

免责声明:香港交易所资讯服务有限公司、其控股公司及／或该等控股公司的任何附属公司均竭力确保所提供信息的准确和可靠度，但不能保证其绝对准确和可靠，且亦不会承担因任何不准确或遗漏而引起的任何损失或损害的责任（不管是否侵权法下的责任或合约责任又或其它责任）

{"stockData":{"symbol":"08037","market":"HK","secType":"STK","nameCN":"中国生物科技服务","latestPrice":0.68,"timestamp":1753430885876,"preClose":0.75,"halted":0,"volume":444000,"delay":0,"floatShares":975731150,"shares":975731150,"eps":-0.204592,"marketStatus":"休市中","change":-0.07,"latestTime":"07-25 16:08:05","open":0.75,"high":0.75,"low":0.68,"amount":310930,"amplitude":0.093333,"askPrice":0.69,"askSize":5000,"bidPrice":0.68,"bidSize":80000,"shortable":0,"etf":0,"ttmEps":-0.204592,"tradingStatus":0,"nextMarketStatus":{"tag":"开盘","tradingStatus":2,"beginTime":1753666200000},"marketStatusCode":7,"adr":0,"listingDate":1087401600000,"exchange":"SEHK","adjPreClose":0.75,"openAndCloseTimeList":[[1753407000000,1753416000000],[1753419600000,1753430400000]],"volumeRatio":0.3338345864912658,"lotSize":5000,"spreadScale":0,"tradeCurrency":"HKD"},"requestUrl":"/m/hq/s/08037","defaultTab":"news","newsList":[{"id":"2554793473","title":"中国生物科技服务(08037)委任尹烨为执行董事","url":"https://stock-news.laohu8.com/highlight/detail?id=2554793473","media":"智通财经","labels":["executive"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2554793473?lang=zh_cn&edition=full","pubTime":"2025-07-25 22:31","pubTimestamp":1753453919,"startTime":"0","endTime":"0","summary":"智通财经APP讯，中国生物科技服务(08037)公布，尹烨博士已获委任为执行董事，张晓博士已获委任为独立非执行董事及审核委员会成员，自2025年7月25日起生效。同日起，钱红骥先生因需要投放更多精力处理其他业务，已辞任独立非执行董事及审核委员会成员。此外，为投放更多时间处理其他事务，林德明先生已辞任该公司公司秘书及公司授权代表，公司财务总监冯佩贤女士已获委任为公司秘书及授权代表。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1322224.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["08037","BK1511","BK1219"],"gpt_icon":0},{"id":"2551941987","title":"中国生物科技服务(08037)：华大松禾以借款转股方式认购 Dynamic Healthcare 持股最多 6.25%","url":"https://stock-news.laohu8.com/highlight/detail?id=2551941987","media":"智通财经","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2551941987?lang=zh_cn&edition=full","pubTime":"2025-07-13 19:24","pubTimestamp":1752405847,"startTime":"0","endTime":"0","summary":"智通财经APP讯，中国生物科技服务 发布公告，有关该投资的正式协议于2025年7月11日订立。在实际上，借款将转换为Dynamic Healthcare的股份。假设A轮融资不涉及对Dynamic Healthcare的其他股份认购，华大松禾将持有经发行认股权证股份及将向嘉博众治(海南)发行的股份扩大后的Dynamic Healthcare已发行股本最多6.25%。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1317091.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["08037","BK1219","BK1511"],"gpt_icon":0},{"id":"2550194671","title":"中国生物科技服务(08037)订立有关硼中子治疗医疗保险产品合作的谅解备忘录","url":"https://stock-news.laohu8.com/highlight/detail?id=2550194671","media":"智通财经","labels":["corporation"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2550194671?lang=zh_cn&edition=full","pubTime":"2025-07-11 06:23","pubTimestamp":1752186210,"startTime":"0","endTime":"0","summary":"智通财经APP讯，中国生物科技服务 发布公告，于2025年7月10日，公司、安盛保险(百慕达)有限公司，于百慕达注册成立的有限公司，及安盛环球再保险(上海)有限公司、前海再保险股份有限公司及Arthur J. Gallagher  Pte. Ltd.订立一份不具法律约束力的谅解备忘录，内容有关共同开发覆盖硼中子治疗治疗费用及相关服务的普惠型医疗保险产品的合作。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1316508.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK1219","08037","BK1511"],"gpt_icon":0},{"id":"2545285529","title":"中证港股通制药与生物科技服务综合指数报824.54点，前十大权重包含晶泰控股等","url":"https://stock-news.laohu8.com/highlight/detail?id=2545285529","media":"金融界","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2545285529?lang=zh_cn&edition=full","pubTime":"2025-06-24 18:09","pubTimestamp":1750759771,"startTime":"0","endTime":"0","summary":"数据统计显示，中证港股通制药与生物科技服务综合指数近一个月上涨7.89%，近三个月下跌1.89%，年至今上涨34.60%。从中证港股通制药与生物科技服务综合指数持仓的市场板块来看，香港证券交易所占比100.00%。遇临时调整时，当中证港股通综合指数调整样本时，样本随之进行相应调整。若中证港股通综合指数样本有特殊事件发生，导致其行业归属发生变化，指数样本进行相应调整。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250624181414978caeff&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250624181414978caeff&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["07226","BK1191","BK1219","BK1141","BK1617","08037","BK1511","HSTECH","02228","01477","BK1574"],"gpt_icon":1},{"id":"2536182507","title":"中国生物科技服务05月19日主力净流入42.9万元 散户资金抛售","url":"https://stock-news.laohu8.com/highlight/detail?id=2536182507","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2536182507?lang=zh_cn&edition=full","pubTime":"2025-05-19 16:15","pubTimestamp":1747642545,"startTime":"0","endTime":"0","summary":"05月19日，中国生物科技服务股价收平报0.70元，成交金额117.1万元，换手率0.16%，振幅11.43%，量比2.09。中国生物科技服务今日主力资金净流入42.9万元，上一交易日主力净流出0万元。该股近5个交易日上涨27.27%，主力资金累计净流入95.0万元，其中1个交易日为股价下跌时净流入；近20日主力资金累计净流入113.2万元，其中净流入天数为3日。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250519173658a483d5f5&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250519173658a483d5f5&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK1219","BK1511","08037"],"gpt_icon":0},{"id":"2535924218","title":"中国生物科技服务：林德明获委任为公司秘书及授权代表","url":"https://stock-news.laohu8.com/highlight/detail?id=2535924218","media":"格隆汇","labels":["executive"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2535924218?lang=zh_cn&edition=full","pubTime":"2025-05-15 16:46","pubTimestamp":1747298785,"startTime":"0","endTime":"0","summary":"格隆汇5月15日丨中国生物科技服务(08037.HK)发布公告，自2025年5月15日起，王妙纯已辞任公司秘书及授权代表，以投放更多时间处理其他事务。自同日起，林德明获委任为公司秘书及授权代表。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250515164625a6e019a4&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250515164625a6e019a4&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["08037","BK1219","BK1511"],"gpt_icon":0},{"id":"2535894458","title":"中国生物科技服务(08037)：林德明获委任为公司秘书及授权代表","url":"https://stock-news.laohu8.com/highlight/detail?id=2535894458","media":"智通财经","labels":["executive"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2535894458?lang=zh_cn&edition=full","pubTime":"2025-05-15 16:34","pubTimestamp":1747298044,"startTime":"0","endTime":"0","summary":"智通财经APP讯，中国生物科技服务(08037)发布公告，自2025年5月15日起，林德明获委任为公司秘书及授权代表。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1293541.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK1219","BK1511","08037"],"gpt_icon":0},{"id":"2533333531","title":"中国生物科技服务(08037)与STELLA PHARMA CORPORATION签署谅解备忘录","url":"https://stock-news.laohu8.com/highlight/detail?id=2533333531","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2533333531?lang=zh_cn&edition=full","pubTime":"2025-05-08 21:16","pubTimestamp":1746710204,"startTime":"0","endTime":"0","summary":"智通财经APP讯，中国生物科技服务 发布公告，于2025年5月8日，本公司、鹏 博(海南)硼中子医疗科技有限公司及STELLA PHARMA CORPORATION订立一份谅解备忘录，有关拟进一步就STEBORONINE在中华人民共和国境内的销售和生产展开合作，作为订约各方持续合作的重要一环。签署谅解备忘录的目的是为了进一步拓展本公司在硼中子治疗产业中的布局。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1291034.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK1219","08037","BK1511"],"gpt_icon":0},{"id":"2533933720","title":"中国生物科技服务(08037)附属将于第18届国际恶性淋巴瘤会议及第30届欧洲血液学年会上展示LY007细胞注射液I期研究临床试验结果","url":"https://stock-news.laohu8.com/highlight/detail?id=2533933720","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2533933720?lang=zh_cn&edition=full","pubTime":"2025-05-07 21:24","pubTimestamp":1746624251,"startTime":"0","endTime":"0","summary":"LY007的临床成果亮点为填补CD20 CAR-T治疗空白。上海隆耀计划于国际恶性淋巴瘤会议与欧洲血液学年会平台，进一步推动LY007 的国际多中心临床研究，并探索与欧美机构的合作。在近一年时间内，上海隆耀LY007的I期临床研究成果在全球各大肿瘤与血液病学术年会上陆续发布，代表着 LY007在全球学术领域获得了认可及关注。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1290478.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK1583","BK1576","BK1141","BK1219","BK1511","08037","03347"],"gpt_icon":0},{"id":"2531202199","title":"中证港股通制药与生物科技服务综合指数报720.61点，前十大权重包含金斯瑞生物科技等","url":"https://stock-news.laohu8.com/highlight/detail?id=2531202199","media":"金融界","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2531202199?lang=zh_cn&edition=full","pubTime":"2025-04-29 17:53","pubTimestamp":1745920406,"startTime":"0","endTime":"0","summary":"数据统计显示，中证港股通制药与生物科技服务综合指数近一个月下跌15.36%，近三个月上涨15.86%，年至今上涨17.63%。从中证港股通制药与生物科技服务综合指数持仓样本的行业来看，制药与生物科技服务占比100.00%。遇临时调整时，当中证港股通综合指数调整样本时，样本随之进行相应调整。若中证港股通综合指数样本有特殊事件发生，导致其行业归属发生变化，指数样本进行相应调整。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2025042917593394e758d1&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2025042917593394e758d1&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["HK0000306701.USD","BK1576","01548","08037","BK1574","HK0000306685.HKD","HK0000320264.USD","HSTECH","BK1583","BK1511","BK1219","HK0000320223.HKD","BK1141","01477","BK1191"],"gpt_icon":1},{"id":"2529609646","title":"中国生物科技服务：银行向本公司附属公司授出授信额度及本公司及控股股东提供担保","url":"https://stock-news.laohu8.com/highlight/detail?id=2529609646","media":"智通财经网","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2529609646?lang=zh_cn&edition=full","pubTime":"2025-04-24 18:24","pubTimestamp":1745490298,"startTime":"0","endTime":"0","summary":"智通财经APP讯，中国生物科技服务 发布公告，关于上海银行浦东分行(贷款人)向本公司的间接非全资附属公司上海隆耀生物科技有限公司提供为期一年的银行授信。实际义务由保证合同的条款管限。根据反担保函，本公司及刘先生为该中心提供无限连带责任反担保。借款合同、保证合同及反担保函的所有条款及条件均经由有关各方按公平原则磋商而厘定。董事认为，有关交易的条款属公平合理，并且符合本公司股东的整体利益。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2025042418271194e0dcd0&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2025042418271194e0dcd0&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK1511","BK1219","08037"],"gpt_icon":0},{"id":"2516680501","title":"中国生物科技服务预计2024财年亏损约1.8亿港元","url":"https://stock-news.laohu8.com/highlight/detail?id=2516680501","media":"财中社","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2516680501?lang=zh_cn&edition=full","pubTime":"2025-03-03 20:05","pubTimestamp":1741003512,"startTime":"0","endTime":"0","summary":"3月3日，中国生物科技服务（08037）发布公告，预计在2024财年将录得公司拥有者应占亏损净额约1.8亿港元，相比2023财年的亏损净额约9545万港元，亏损大幅增加约8455万港元。董事会指出，亏损增加的主要原因包括COVID-19核酸检测需求减少，市场竞争加剧，导致收入下降。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://finance.eastmoney.com/a/202503033334998983.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_eastmoney","symbols":["08037","BK1219","BK1511"],"gpt_icon":0},{"id":"2514389075","title":"中国生物科技服务(08037)：湖北惟宥拟向鹏博(海南)注资最多5000万元","url":"https://stock-news.laohu8.com/highlight/detail?id=2514389075","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2514389075?lang=zh_cn&edition=full","pubTime":"2025-02-27 23:25","pubTimestamp":1740669904,"startTime":"0","endTime":"0","summary":"在注资额人民币5000万元中，人民币1666.67万元将入账作为鹏博(海南)的注册资本，其余人民币3333.33万元将入账至股份溢价账。本公司认为，注资协议及其项下拟进行的交易将为硼中子俘获治疗中心的发展提供更多资金。此外，注资所得款项最多人民币5000万元预期将用于清偿鹏博(海南)现有贷款;及硼中子俘获治疗中心的建设、开发及营运。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1255821.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK1219","BK1511","08037"],"gpt_icon":0},{"id":"2514614022","title":"中国生物科技服务与华大基因签署战略合作协议","url":"https://stock-news.laohu8.com/highlight/detail?id=2514614022","media":"财中社","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2514614022?lang=zh_cn&edition=full","pubTime":"2025-02-26 09:22","pubTimestamp":1740532955,"startTime":"0","endTime":"0","summary":"2月26日，中国生物科技服务（08037）发布公告，宣布与深圳华大基因科技有限公司签署了战略合作框架协议，并与鹏博（海南）硼中子医疗科技有限公司签署了投资意向书。框架协议的主要内容包括双方将在BNCT治疗合作、CAR-T治疗研究和应用、治疗后监测和疗效评估、肿瘤精准诊断与筛查等领域进行合作，目标是推动相关技术在中国的临床应用与学术推广。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://finance.eastmoney.com/a/202502263329802187.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_eastmoney","symbols":["08037","BK1511","BK1219"],"gpt_icon":0},{"id":"2514902999","title":"中国生物科技服务与深圳华大基因科技订立战略合作框架协议","url":"https://stock-news.laohu8.com/highlight/detail?id=2514902999","media":"新浪港股","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2514902999?lang=zh_cn&edition=full","pubTime":"2025-02-26 08:16","pubTimestamp":1740528960,"startTime":"0","endTime":"0","summary":"　　中国生物科技服务发布公告，于2025年2月25日， 公司与深圳华大基因科技有限公司订立战略合作框架协议：双方联合开展基于BNCT治疗的临床研究，推动BNCT技术在中国境内的临床应用和学术推广。　　华大与公司在肿瘤精准诊断、治疗及技术研发领域具有互补性，并愿意基于平等互利，合作共赢，共同发展的原则开展长期战略合作。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.sina.com.cn/stock/hkstock/ggscyd/2025-02-26/doc-inemuerp0636657.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"sina","symbols":["BK0197","BK0042","300676","BK0221","BK1511","BK1219","BK0046","08037","BK0196"],"gpt_icon":0},{"id":"2514097965","title":"【中国生物科技服务(08037.HK)与深圳华大基因科技订立战略合作框架协议】中国生物科技服务(08037.HK)发布公告，于2025年2月25日， 公司与深圳华大基因科技有限公司(深圳华大科技)订立战略合作框架协议：(1)双方联合开展基于BNCT治疗的临床研究，推动BNCT技术在中国境内的临床应用和学术推广。(2)双方联合开展基于新型靶向CD20 CAR-T治疗方法的学术研究，共同探索临床应用和推广转化的商业路径，推动该新型治疗方法助益更广泛适宜患者人群。","url":"https://stock-news.laohu8.com/highlight/detail?id=2514097965","media":"金融界","labels":["corporation"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2514097965?lang=zh_cn&edition=full","pubTime":"2025-02-25 22:22","pubTimestamp":1740493354,"startTime":"0","endTime":"0","summary":"中国生物科技服务(08037.HK)发布公告，于2025年2月25日， 公司与深圳华大基因科技有限公司(深圳华大科技)订立战略合作框架协议：(1)双方联合开展基于BNCT治疗的临床研究，推动BNCT技术在中国境内的临床应用和学术推广。(2)双方联合开展基于新型靶向CD20 CAR-T治疗方法的学术研究，共同探索临床应用和推广转化的商业路径，推动该新型治疗方法助益更广泛适宜患者人群。","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://24h.jrj.com.cn/2025/02/25222248383570.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":"jinrongjie_stock","symbols":["BK1511","CAR","BK1219","BK0197","08037","BK4022","BK4230","BK0196","BK0042","BK0046","BK0221","300676"],"gpt_icon":0},{"id":"2514097882","title":"中国生物科技服务(08037)与深圳华大基因科技订立战略合作框架协议","url":"https://stock-news.laohu8.com/highlight/detail?id=2514097882","media":"智通财经","labels":["corporation"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2514097882?lang=zh_cn&edition=full","pubTime":"2025-02-25 22:17","pubTimestamp":1740493070,"startTime":"0","endTime":"0","summary":"智通财经APP讯，中国生物科技服务 发布公告，于2025年2月25日， 公司与深圳华大基因科技有限公司订立战略合作框架协议：双方联合开展基于BNCT治疗的临床研究，推动BNCT技术在中国境内的临床应用和学术推广。深圳华大科技作为优先合作伙伴，为公司提供肿瘤治疗后检测产品和解决方案，用于患者治疗后的效果监测评估及长期随访。海南博鳌BNCT硼中子治疗中心计划于2025年第四季度开业。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1254321.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK0046","BK0042","08037","300676","BK0196","BK0221","BK1219","BK0197","BK1511"],"gpt_icon":0},{"id":"2514092007","title":"中国生物科技服务与深圳华大基因签署战略合作框架协议","url":"https://stock-news.laohu8.com/highlight/detail?id=2514092007","media":"格隆汇","labels":["corporation"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2514092007?lang=zh_cn&edition=full","pubTime":"2025-02-25 22:13","pubTimestamp":1740492787,"startTime":"0","endTime":"0","summary":"格隆汇2月25日丨中国生物科技服务公告，于2025年2月25日，公司与深圳华大基因科技有限公司订立战略合作框架协议；及鹏博(海南)硼中子医疗科技有限公司与深圳市华大松禾生科一号私募创业投资基金合伙企业订立投资意向书，内容有关于投资人拟对鹏博(海南)进行投资。深圳华大科技的控股股东间接拥有投资人约24%权益。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250225221307abdc79d6&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250225221307abdc79d6&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK1219","08037","BK1511"],"gpt_icon":0},{"id":"2512846414","title":"中国生物科技服务股价拉升11.90% 市值涨5457.22万港元","url":"https://stock-news.laohu8.com/highlight/detail?id=2512846414","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2512846414?lang=zh_cn&edition=full","pubTime":"2025-02-20 11:49","pubTimestamp":1740023395,"startTime":"0","endTime":"0","summary":"2025年02月20日临近午盘11时49分，中国生物科技服务股票出现异动，股价大幅上涨11.90%。截至发稿，该股报0.470港元/股，成交量10000股，换手率0.00%，振幅0.00%。中国生物科技服务股票所在的医疗及医学美容服务行业中，整体跌幅为0.01%。其相关个股中，中国生物科技服务、金威医疗、海吉亚医疗涨幅较大，振幅较大的相关个股有梅斯健康、医思健康、北京健康，振幅分别为25.00%、15.71%、12.99%。中国生物科技服务公司简介：本公司之主要业务为投资控股。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2025022011495596296c6a&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2025022011495596296c6a&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["08037","BK1219","BK1511"],"gpt_icon":0}],"profile":{"websiteUrl":"http://www.ruikang.com.hk","stockEarnings":[{"period":"1week","weight":-0.0423},{"period":"1month","weight":0.0462},{"period":"3month","weight":0.863},{"period":"6month","weight":0.7895},{"period":"1year","weight":0.863},{"period":"ytd","weight":0.3333}],"compareEarnings":[{"period":"1week","weight":0.0227},{"period":"1month","weight":0.0373},{"period":"3month","weight":0.155},{"period":"6month","weight":0.2652},{"period":"1year","weight":0.493},{"period":"ytd","weight":0.2656}],"compareStock":{"symbol":"HSI","name":"恒生指数"},"description":"中国生物科技服务控股有限公司（原名：锐康药业集团投资有限公司）是一家主要从事提供医学检测服务的投资控股公司。该公司通过六个分部运营业务。医学及保健相关服务分部主要提供医学实验室检测服务及健康检查服务。保险经纪分部主要提供保险经纪服务。免疫治疗分部主要提供肿瘤免疫细胞治疗、免疫细胞存储及健康管理服务。医药产品分部主要制造、研发、销售及分销保健相关及医药产品。证券分部主要从事买卖证券业务。其他分部主要从事放债业务及提供物流服务。","yearOnYearQuotes":[{"month":1,"riseRate":0.190476,"avgChangeRate":-0.025851},{"month":2,"riseRate":0.47619,"avgChangeRate":0.104887},{"month":3,"riseRate":0.333333,"avgChangeRate":-0.063234},{"month":4,"riseRate":0.285714,"avgChangeRate":-0.007021},{"month":5,"riseRate":0.714286,"avgChangeRate":0.103641},{"month":6,"riseRate":0.428571,"avgChangeRate":-0.012662},{"month":7,"riseRate":0.363636,"avgChangeRate":-0.031808},{"month":8,"riseRate":0.285714,"avgChangeRate":-0.022682},{"month":9,"riseRate":0.190476,"avgChangeRate":-0.041254},{"month":10,"riseRate":0.333333,"avgChangeRate":0.026661},{"month":11,"riseRate":0.428571,"avgChangeRate":0.03812},{"month":12,"riseRate":0.52381,"avgChangeRate":-0.002982}],"exchange":"SEHK","name":"中国生物科技服务","nameEN":"CH BIOTECH SER"},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"deviceId":"web-server-community-laohu8-v3","version":"4.34.4","shortVersion":"4.34.4","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"中国生物科技服务(08037)_个股概要_股票价格_最新资讯_行情走势_历史数据","description":"美港股上老虎。老虎社区提供中国生物科技服务(08037)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","keywords":"中国生物科技服务,08037,中国生物科技服务股票,中国生物科技服务股票老虎,中国生物科技服务股票老虎国际,中国生物科技服务行情,中国生物科技服务股票行情,中国生物科技服务股价,中国生物科技服务股市,中国生物科技服务股票价格,中国生物科技服务股票交易,中国生物科技服务股票购买,中国生物科技服务股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"中国生物科技服务(08037)_个股概要_股票价格_最新资讯_行情走势_历史数据","og_description":"美港股上老虎。老虎社区提供中国生物科技服务(08037)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","og_image":"https://static.tigerbbs.com/a0b84b8debbbce3b4440f7fdd5eed2e7"}}}